Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of brigatinib as second-line treatment for ROS1-positive NSCLC after crizotinib
MOH_2019-02-18_003723Phase 2Not yet recruiting
- Sponsor
- פרופ' ניר פלד
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of brigatinib in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer (NSCLC), sponsored by פרופ' ניר פלד. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2019-02-18_003723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-02-18_003723.